Fresenius Recognizes Aged Patients - Analyst Blog

By
A A A

Fresenius Medical Care North America ("FMCNA"), the North American division of Fresenius Medical Care ( FMS ), recently revealed that it is recognizing over 25 patients in the U.S. who will turn 100 years or more in age in 2012. These individuals are carrying on with active, wholesome lives even though they lack proper kidney function.

Dialysis is a life-sustaining mechanism that purifies waste products from the blood stream and regulates the chemistry of the body when an individual is struck with kidney failure. Dialysis patients invariably need this ongoing therapy until they are recipients of kidney transplant.  

Thanks to dialysis treatment, victims of kidney failure are now bestowed with a higher probability of leading high quality life style for several years. The company stated that important attributes for faring well on dialysis include commitment to the planned treatment and adjustment of lifestyle, particularly exercise and dietary matters.

Some of the centenarian patients of FMCNA have been on dialysis for several years. Each year, FMCNA identifies about 350 individuals with its Quarter Century Patient Recognition Program, which felicitates individuals who have undergone treatment for a quarter century or longer.  

One factor that prolongs longevity of kidney patients is the wide array of available treatment options. FMCNA is determined to provide a wide range of services to its beneficiaries.

In addition, FMCNA provides educational programs at no extra cost via its Treatment Options Program. These programs are intended to educate victims about different treatment options and urges them to find the treatment that most benefits them.

Dialysis patients can now avail of noteworthy technical progress in the field of dialysis treatment. FMCNA has over 30 years of expertise in dialysis treatment and its technology is capable of both purifying blood and facilitating a balanced life for patients on dialysis.

A large proportion of dialysis patients attribute their longevity to maintaining treatment, exercising periodically and eating wholesome food, besides pursuing a busy life style. Dialysis patients who both recognize their condition and are committed to their treatment regimen are expected to harvest optimal results from dialysis.     

Fresenius is the largest provider of dialysis products and services on the planet. The company operates a network of about 2,874 dialysis clinics across North America and overseas markets to provide dialysis treatment to approximately 228,239 patients, as of September 30, 2011. Fresenius' principal competitor in the U.S. is DaVita Inc. ( DVA ), which also provides dialysis services to patients suffering from chronic kidney failure or ESRD.


 
DAVITA INC ( DVA ): Free Stock Analysis Report
 
FRESENIUS MED ( FMS ): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: DVA , FMS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

84,725,997
  • $6.69 ▼ 5.11%
68,180,500
  • $3.38 ▼ 1.74%
52,748,572
  • $99.02 ▲ 1.38%
40,996,811
  • $74.92 ▼ 0.36%
37,831,986
  • $15.50 ▼ 0.58%
34,013,720
  • $31.98 ▼ 4.31%
32,417,159
  • $25.59 ▼ 0.78%
31,985,971
  • $54.87 ▲ 1.20%
As of 7/28/2014, 04:05 PM